NCT07183423 Novel Skin Barrier Product Versus Petrolatum for Skin Barrier Dysfunction
| NCT ID | NCT07183423 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Makati Medical Center |
| Condition | Psoriasis |
| Study Type | INTERVENTIONAL |
| Enrollment | 26 participants |
| Start Date | 2025-08-31 |
| Primary Completion | 2025-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 26 participants in total. It began in 2025-08-31 with a primary completion date of 2025-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn if a novel barrier topical product works to treat barrier dysfunction in adults. It will also learn about the safety of the novel barrier topical product. The main questions it aims to answer are: Does the novel barrier topical product improve skin hydration, skin sebum, redness, and pigmentation? Does it improve subjective dryness and itch? Researchers will compare the novel barrier topical product to petrolatum (a gold standard occlusive barrier repair agent) to see how they are comparable in treating skin barrier dysfunction. Participants will: Apply the novel barrier topical product or petrolatum twice a day for 28 days Visit the clinic once a week for checkups and tests Keep a diary of their application of the assigned product
Eligibility Criteria
Inclusion Criteria: * Clinical diagnosis of mild skin barrier dysfunction, including: * Mild to moderate atopic dermatitis, defined as SCORAD ≤ 50, and/or not currently requiring topical corticosteroids or immunomodulators. * Mild to moderate chronic plaque psoriasis, defined as total body surface area (BSA) involved: ≤3% to 10%. * Contact dermatitis * Seasonal xerosis or clinically evident skin dryness * Symmetrical or bilateral test areas available (volar forearm) * Willing and able to provide informed consent and adhere to study procedures Exclusion Criteria: * Failure to meet any of the above inclusion criteria * Severe atopic dermatitis or psoriasis requiring systemic or high-potency topical treatment * Use of corticosteroids, calcineurin inhibitors, biologics, or phototherapy within 2 weeks * Open wounds or evidence of secondary infection at test sites * Pregnant or breastfeeding women * Multiple nevi, tattoos, dense body hair in the test areas * Debilitated or immunocompromised subjects * Known or suspected hypersensitivity to the interventional product (or its ingredients) or petrolatum * Refusal or failure to comply with the schedule of visits at the test site.
Contact & Investigator
Vermen M Verallo Rowell, MD
PRINCIPAL INVESTIGATOR
VMV Skin Research Center & Clinics
Frequently Asked Questions
Who can join the NCT07183423 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Psoriasis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07183423 currently recruiting?
Yes, NCT07183423 is actively recruiting participants. Contact the research team at ccvrowell@gmail.com for enrollment information.
Where is the NCT07183423 trial being conducted?
This trial is being conducted at Makati City, Philippines.
Who is sponsoring the NCT07183423 clinical trial?
NCT07183423 is sponsored by Makati Medical Center. The principal investigator is Vermen M Verallo Rowell, MD at VMV Skin Research Center & Clinics. The trial plans to enroll 26 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.